Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Brisbane, California. It specializes in the discovery, development and commercialization of targeted protein degradation medicines for cancer and autoimmune diseases. The company’s lead program is bexobrutideg (NX-5948), an oral, brain-penetrant BTK degrader currently advancing toward Phase 3 trials in chronic lymphocytic leukemia and other indications.
In June 2026, Nurix entered a global collaboration with Roche to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology and neurology. Under the agreement, Nurix receives an upfront payment of USD 700 million and is eligible for up to USD 2.3 billion in milestones, with shared U.S. profits and royalties outside the United States. Nurix also maintains collaborations with Gilead Sciences, Sanofi and Pfizer.
Also known as Nurix Inc. and Kura Therapeutics, Inc..
Collaboration targets B‑cell malignancies, immunology and neurology with an oral, brain‑penetrant BTK degrader planned for Phase 3 in summer 2026.
